CTLA4 and osteosarcoma: In addition, analysis of five immune checkpoints in osteosarcoma patients showed that the expressions of CTLA4, TIM3, LAG3, and TIGIT in the samples with low risk scores were markedly elevated compared with those with high risk scores, suggesting that patients with low risk scores might be sensitive to the treatment targeting immune checkpoints.